Moneycontrol PRO
HomeNewsTorrent pharma

Torrent Pharma

Jump to
  • Torrent Pharma Consolidated September 2025 Net Sales at Rs 3,302.00 crore, up 14.3% Y-o-Y

  • Neutral Torrent Pharma; target of Rs 3770: Motilal Oswal

    Motilal Oswal recommended Neutral rating on Torrent Pharma with a target price of Rs 3770 in its research report dated November 08, 2025.

  • Torrent Pharma Standalone September 2025 Net Sales at Rs 2,762.00 crore, up 13.48% Y-o-Y

  • Hold Torrent Pharma: target of Rs 3530 : ICICI Securities

    ICICI Securities recommended hold rating on Torrent Pharma with a target price of Rs 3530 in its research report dated November 09, 2025.

  • Torrent Pharma Q2 net profit jumps 30% to Rs 591 crore

    The company said its India revenue stood at Rs 1,820 crore during the period under review, up 12 per cent, led by outperformance in focus therapies

  • Hold Torrent Pharma: target of Rs 3530: ICICI Securities

    ICICI Securities recommended hold rating on Torrent Pharma with a target price of Rs 3530 in its research report dated July 29, 2025.

  • Torrent Pharma Consolidated June 2025 Net Sales at Rs 3,178.00 crore, up 11.16% Y-o-Y

  • Torrent Pharma Standalone June 2025 Net Sales at Rs 2,616.00 crore, up 7.3% Y-o-Y

  • Torrent Pharma Q1 net profit up 20% at Rs 548 crore

    The company's India revenues rose by 11% YoY to Rs 1,811 crore in the April-June period.

  • Hold Torrent Pharma; target of Rs 3500: ICICI Securities

    ICICI Securities recommended hold rating on Torrent Pharma with a target price of Rs 3500 in its research report dated July 01, 2025.

  • Gainers & Losers: Top 10 stocks that moved the most on June 30

    At close, the Sensex was down 452.44 points or 0.54 percent at 83,606.46, and the Nifty was down 124.00 points or 0.48 percent at 25,513.80. About 2,151 shares advanced, 1,538 shares declined, and 133 shares unchanged.

  • Neutral Torrent Pharma; target of Rs 3430: Motilal Oswal

    Motilal Oswal recommended Neutral rating on Torrent Pharma with a target price of Rs 3430 in its research report dated June 30, 2025.

  • Quick Take: Torrent Pharma puts the money where its heart is

    Torrent’s India business has been outperforming the domestic market

  • Torrent Pharma shares rise 4% after Rs 25,689-crore JB Chemicals deal; HSBC maintains buy

    Torrent Pharma share price: The deal is expected to strengthen Torrent's market share in the Indian pharmaceutical market and diversify its platform into contract development and manufacturing.

  • Torrent Pharma to acquire controlling stake in JB Pharma from KKR at Rs 25,689 crore valuation

    The transaction between Torrent and JB Pharma will unfold in two distinct phases

  • Torrent Pharma revives talks to acquire KKR’s stake in JB Pharma; deal expected soon

    KKR’s stake is worth approximately Rs 13,400 crore considering the J B Pharma stock’s closing price of Rs 1,802.9 per share on June 27.

  • Torrent Pharma Standalone March 2025 Net Sales at Rs 2,433.00 crore, up 13.53% Y-o-Y

  • Neutral Torrent Pharma; target of Rs 3410: Motilal Oswal

    Motilal Oswal recommended Neutral rating on Torrent Pharma with a target price of Rs 3410 in its research report dated January 25, 2025.

  • Torrent Pharma Consolidated December 2024 Net Sales at Rs 2,809.00 crore, up 2.82% Y-o-Y

  • Torrent Pharma Standalone December 2024 Net Sales at Rs 2,377.00 crore, up 11.96% Y-o-Y

  • Torrent Pharma's Q3 net profit jumps 14% to Rs 503 crore; declares Rs 26/share interim dividend

    The pharmaceutical firm’s net profit stood at Rs 453 crore in the September quarter, the stock filing showed

  • Q3 Results 2025 LIVE: IndiGo will have 40 planes with business class seats by the end of 2025

    Earlier yesterday, UltraTech Cement, Dr Reddy’s Labs, Hindustan Petroleum, Mphasis, Zee, Indus Towers, Adani Green Energy, Adani Energy Solutions, Cyient Limited, Mankind Pharma and United Spirits announced their Q3 results.

  • Torrent Pharma strengthens anti-diabetes portfolio with acquisition of three brands from Boehringer

    "The acquisition is expected to be completed in March 2025. Torrent has been marketing these brands since 2022 as part of an existing co-marketing agreement with Boehringer Ingelheim India," the company said in a statement.

  • Torrent Pharma Standalone September 2024 Net Sales at Rs 2,434.00 crore, up 13.42% Y-o-Y

  • Torrent Pharma shares rise after USFDA closes inspection with 'Voluntary Action' classification

    The inspection was conducted by USFDA for Torrent's manufacturing facility at Pithampur, Madhya Pradesh between September 16-20, 2024.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347